Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
Daewoong Pharmaceutical Co. LTD.
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07371104CT.gov Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer | — | Recruiting | — | — | — |
NCT07453394CT.gov QLS5132 Combination Therapy in Advanced Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT07382544CT.gov Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss | — | Recruiting | — | — | — |
NCT07156253CT.gov Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT06686745CT.gov Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06560632CT.gov Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT06525298CT.gov EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors | — | Recruiting | — | — | — |
NCT06545942CT.gov Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05932862CT.gov A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06331559CT.gov Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
Show 19 more trialsShow fewer
NCT06130254CT.gov Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers | — | Terminated | — | — | — |
NCT05898399CT.gov Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA) | — | Recruiting | — | — | — |
NCT05933265CT.gov Study of LP-184 in Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05498272CT.gov Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations | — | Recruiting | — | — | — |
NCT05252390CT.gov NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05043922CT.gov A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma | — | Active Not Recruiting | — | — | — |
NCT05240898CT.gov A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03878095CT.gov Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors | — | Active Not Recruiting | — | — | — |
NCT03669601CT.gov AZD6738 & Gemcitabine as Combination Therapy | — | Unknown | — | — | — |
NCT03568656CT.gov Study to Evaluate CCS1477 in Advanced Tumours | — | Completed | — | — | — |
NCT03297606CT.gov Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | — | Recruiting | — | — | — |
NCT02693535CT.gov TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | — | Recruiting | — | — | — |
NCT02576444CT.gov OLAParib COmbinations | — | Terminated | — | — | — |
NCT02684318CT.gov Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors | — | Unknown | — | — | — |
NCT02418624CT.gov Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer | — | Completed | — | — | — |
NCT02338622CT.gov Trial of Olaparib in Combination With AZD5363 (ComPAKT) | — | Completed | — | — | — |
NCT02227082CT.gov Olaparib and Radiotherapy in Inoperable Breast Cancer | — | Completed | — | — | — |
NCT01813474CT.gov Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies | — | Completed | — | — | — |
NCT00782574CT.gov Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Olaparib (this asset) | Daewoong Pharmaceutical Co. LTD. | P2 | CCC · 55 |
| Nabiximols | Jazz Pharmaceuticals | P3 | BBB |
| Pyridoxol | M.D. Anderson Cancer Center | P4 | BB |
| Rivoceranib | Jiangsu HengRui Medicine Co., Ltd. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Propofol | Hong Kong Children's Hospital | P4 | BB |
| Epirubicin | Zhejiang Provincial People's Hospital | P3 | BB |
| Atorvastatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P2/3 | BB |
| Anamorelin | Helsinn Healthcare SA | P3 | BB |
+42 more in the Cancer cohort
Other indications for Olaparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P4 | BBB · 73 |
| Fallopian Tube Serous Adenocarcinoma | — | P3 | BBB · 72 |
| Ovarian Carcinoma | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Olaparib in Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/olaparib-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →